CY1109790T1 - Παραγωγα συντηγμενου αζολιου-πυριμιδινης - Google Patents

Παραγωγα συντηγμενου αζολιου-πυριμιδινης

Info

Publication number
CY1109790T1
CY1109790T1 CY20091100017T CY091100017T CY1109790T1 CY 1109790 T1 CY1109790 T1 CY 1109790T1 CY 20091100017 T CY20091100017 T CY 20091100017T CY 091100017 T CY091100017 T CY 091100017T CY 1109790 T1 CY1109790 T1 CY 1109790T1
Authority
CY
Cyprus
Prior art keywords
disease
present
diseases
derivatives
disorders
Prior art date
Application number
CY20091100017T
Other languages
Greek (el)
English (en)
Inventor
Mitsuyuki Shimada
Toshiki Murata
Kinji Fuchikami
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Urbahns
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CY1109790T1 publication Critical patent/CY1109790T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CY20091100017T 2002-09-30 2009-01-09 Παραγωγα συντηγμενου αζολιου-πυριμιδινης CY1109790T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30
EP03788908A EP1549652B1 (en) 2002-09-30 2003-09-18 Fused azole-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CY1109790T1 true CY1109790T1 (el) 2014-09-10

Family

ID=32039115

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100017T CY1109790T1 (el) 2002-09-30 2009-01-09 Παραγωγα συντηγμενου αζολιου-πυριμιδινης
CY20111100771T CY1112174T1 (el) 2002-09-30 2011-08-10 Παραγωγα συντηγμενης αζολο-πυριμιδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100771T CY1112174T1 (el) 2002-09-30 2011-08-10 Παραγωγα συντηγμενης αζολο-πυριμιδινης

Country Status (33)

Country Link
US (2) US7511041B2 (und)
EP (2) EP1549652B1 (und)
JP (1) JP4790266B2 (und)
KR (1) KR101059652B1 (und)
CN (1) CN100384846C (und)
AR (2) AR041426A1 (und)
AT (2) ATE411996T1 (und)
AU (1) AU2003293310B2 (und)
BR (1) BRPI0314830B8 (und)
CA (1) CA2499134C (und)
CY (2) CY1109790T1 (und)
DE (1) DE60324296D1 (und)
DK (2) DK1549652T3 (und)
EC (2) ECSP055768A (und)
ES (2) ES2367141T3 (und)
HK (1) HK1084393A1 (und)
HR (2) HRP20050375B1 (und)
IL (1) IL166855A (und)
MA (1) MA27483A1 (und)
MX (1) MXPA05001808A (und)
MY (1) MY140756A (und)
NO (1) NO331457B1 (und)
NZ (1) NZ539062A (und)
PE (1) PE20050089A1 (und)
PL (1) PL226562B1 (und)
PT (2) PT1549652E (und)
RU (1) RU2326881C9 (und)
SI (2) SI1549652T1 (und)
TW (1) TWI327570B (und)
UA (1) UA82205C2 (und)
UY (1) UY28001A1 (und)
WO (1) WO2004029055A1 (und)
ZA (1) ZA200503306B (und)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
KR100878737B1 (ko) 2003-08-29 2009-01-14 미쓰이 가가쿠 가부시키가이샤 농업용 또는 원예용 살충제 및 그의 이용 방법
EP3943494A1 (en) 2004-05-13 2022-01-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MX2007004051A (es) 2004-10-07 2007-05-24 Boehringer Ingelheim Int Pi3-quinasas.
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
CA2605158A1 (en) 2005-04-14 2006-10-26 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
AU2006278998A1 (en) * 2005-07-29 2007-02-15 4Sc Ag Novel heterocyclic NF-kB inhibitors
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
PT2041139E (pt) * 2006-04-26 2012-01-13 Hoffmann La Roche Compostos farmacêuticos
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (en) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
JP2010539239A (ja) * 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
EP2193211A4 (en) * 2007-09-19 2010-12-08 Univ Boston IDENTIFICATION OF NEW PATHWAYS FOR THE DEVELOPMENT OF MEDICINES FOR THE TREATMENT OF LUNG DISEASES
EP2244721A4 (en) * 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
WO2009128520A1 (ja) * 2008-04-18 2009-10-22 塩野義製薬株式会社 Ｐ１３ｋ阻害活性を有する複素環化合物
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
JP5403709B2 (ja) * 2008-11-11 2014-01-29 ジェ イル ファーマシューティカル カンパニー リミテッド 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US20100202963A1 (en) 2008-11-13 2010-08-12 Gallatin W Michael Therapies for hematologic malignancies
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 ２―퓨리닐―３―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
CN102458410A (zh) 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
EA021056B1 (ru) * 2009-04-30 2015-03-31 Глаксо Груп Лимитед Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ, содержащая их фармацевтическая композиция и их применение в лечении расстройств, опосредованных ненадлежащей активностью pi3-киназ
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
SG179085A1 (en) * 2009-09-09 2012-04-27 Avila Therapeutics Inc Pi3 kinase inhibitors and uses thereof
MX2012012064A (es) * 2010-04-16 2012-12-17 Bayer Ip Gmbh Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
KR20130099117A (ko) 2010-10-01 2013-09-05 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 ｎ-(2-아릴아미노)아릴 설폰아미드 함유 배합물
ES2639402T3 (es) * 2010-11-11 2017-10-26 Bayer Intellectual Property Gmbh 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CA2817312A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
SI2834241T1 (sl) 2012-03-05 2021-06-30 Gilead Calistoga Llc Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
EP3626308A1 (en) 2013-03-14 2020-03-25 Veracyte, Inc. Methods for evaluating copd status
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014166820A1 (en) 2013-04-08 2014-10-16 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
IL296526A (en) 2013-05-01 2022-11-01 Hoffmann La Roche Biheteroaryl compounds and their uses
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CA2978830A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2018009915A1 (en) 2016-07-08 2018-01-11 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
AU2017376766A1 (en) 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
WO2018153980A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
ES2950663T3 (es) 2017-09-08 2023-10-11 Bayer Pharma AG Formulaciones de copanlisib
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
MX2020003126A (es) * 2017-09-20 2020-10-01 Abm Therapeutics Corp Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
TW202038957A (zh) 2018-12-21 2020-11-01 日商第一三共股份有限公司 抗體-藥物結合物與激酶抑制劑之組合
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236A (zh) * 2022-04-25 2022-06-14 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
KR100290129B1 (ko) 1994-08-12 2001-05-15 마이클 바마트 옥시퓨린 누클레오시드로 패혈증 또는 염증성 질병을 치료하는 방법
EP0885192B8 (en) * 1996-01-29 2012-05-16 The United States of America, Represented by the Secretary, Department of Health and Human Services Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
JP3649395B2 (ja) * 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体

Also Published As

Publication number Publication date
CA2499134C (en) 2011-12-20
US20060128732A1 (en) 2006-06-15
BRPI0314830B1 (pt) 2018-03-27
ECSP11005768A (es) 2011-03-31
MA27483A1 (fr) 2005-08-01
HRP20131159A2 (hr) 2014-05-23
JP2006508063A (ja) 2006-03-09
ECSP055768A (es) 2005-08-11
DE60324296D1 (de) 2008-12-04
RU2326881C2 (ru) 2008-06-20
IL166855A (en) 2014-05-28
PT1549652E (pt) 2008-12-15
BR0314830A (pt) 2005-08-16
TWI327570B (en) 2010-07-21
WO2004029055A1 (en) 2004-04-08
AU2003293310B2 (en) 2010-04-01
UA82205C2 (en) 2008-03-25
SI1549652T1 (sl) 2009-04-30
AR072458A2 (es) 2010-09-01
UY28001A1 (es) 2004-04-30
CN1688582A (zh) 2005-10-26
CA2499134A1 (en) 2004-04-08
CN100384846C (zh) 2008-04-30
TW200413379A (en) 2004-08-01
BRPI0314830B8 (pt) 2021-05-25
EP1549652A1 (en) 2005-07-06
HK1084393A1 (en) 2006-07-28
ES2367141T3 (es) 2011-10-28
RU2326881C9 (ru) 2009-04-10
MY140756A (en) 2010-01-15
PL226562B1 (pl) 2017-08-31
RU2005113165A (ru) 2005-10-10
EP1549652B1 (en) 2008-10-22
HRP20050375A2 (en) 2006-05-31
MXPA05001808A (es) 2005-08-16
KR20050067404A (ko) 2005-07-01
CY1112174T1 (el) 2015-12-09
AR041426A1 (es) 2005-05-18
US20090270388A1 (en) 2009-10-29
EP2042504A1 (en) 2009-04-01
US7511041B2 (en) 2009-03-31
US8129386B2 (en) 2012-03-06
NO20052076L (no) 2005-04-27
ES2312843T3 (es) 2009-03-01
DK1549652T3 (da) 2009-02-23
ZA200503306B (en) 2006-07-26
PL375935A1 (en) 2005-12-12
DK2042504T3 (da) 2011-09-19
HRP20050375B1 (hr) 2014-03-14
PE20050089A1 (es) 2005-04-20
ATE511510T1 (de) 2011-06-15
PT2042504E (pt) 2011-09-07
KR101059652B1 (ko) 2011-08-25
JP4790266B2 (ja) 2011-10-12
EP2042504B1 (en) 2011-06-01
HRP20131159B1 (hr) 2019-11-01
SI2042504T1 (sl) 2011-10-28
NZ539062A (en) 2007-05-31
AU2003293310A1 (en) 2004-04-19
NO331457B1 (no) 2012-01-09
ATE411996T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
CY1109790T1 (el) Παραγωγα συντηγμενου αζολιου-πυριμιδινης
CY1108746T1 (el) Παραγωγα 2-φαινοξυ- και 2-φαινυλοσουλφοναμιδιου με ανταγωνιστικη δραστικοτητα ccr3 για την θεραπεια του ασθματος και αλλων φλεγμονωδων ή ανοσολογικων διαταραχων
CY1126056T1 (el) Νεα παραγωγα αμινοπυριμιδινης
CY1106748T1 (el) Ν-(3,3-dimethylindolin-6-yl){2-[(4-pyridylmethyl) amino}(3-pyridyl)}carboxamide και φαρμακευτικες συνθεσεις της
MXPA04004019A (es) Derivados de pirimido?4,5-b?indol.
DE60141895D1 (de) Substituierte beta-carboline mit ikb-kinase hemmender wirkung
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
ATE404552T1 (de) Substituierte isochinolinderivate und anwendungsverfahren
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
EA200200249A1 (ru) Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов
CY1107856T1 (el) Παραγωγα ιμιδαζολιου ως ανταγωνιστες υποδοχεα γλουταμινικου
NO20052591L (no) Pyridopyrolizin og pyridoindolizinderivater
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
NO20064895L (no) 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer
CO5700775A2 (es) Nuevos derivados triciclicos como antagonistas de ltd4
EA200700116A1 (ru) Четвертичные соли, антагонисты ccr2
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
UA90707C2 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
CY1109076T1 (el) Παραγωγα της 4- phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για θεραπεια της στειροτητας
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
NO20091577L (no) Nye 5,7-disubstituerte (1,3)tiazolo[4,5-D]pyrimidin-2(3H)-aminderivater og deres anvendelse i terapi
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
DE602006017849D1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors